PARADISE-MI

A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to Ramipril in acute MI patients with evidence of LV dysfunction (but without prior history of chronic HF)

Stadium
klaar
Middel
LCZ696
Populatie
ASCVD
Fase
III
First Patient In
9 februari 2017
Last Patient In
17 april 2020
Last Patient Last Visit
16 februari 2021

National Lead

dr. P van der Meer

Cardioloog

Studiedirecteur

dr M.E. Emans

Cardioloog

De pagina is verlopen.